Predictors of the therapeutic effect of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome
© The Author(s). 2016
Received: 17 February 2016
Accepted: 1 July 2016
Published: 24 August 2016
Sivelestat, a neutrophil elastase inhibitor, was previously approved in Japan for the treatment of acute lung injury associated with systemic inflammatory response syndrome. However, sivelestat produced inconsistent therapeutic benefits. This study aimed to identify factors predicting the therapeutic effects of sivelestat.
We enrolled 53 mechanically ventilated patients who received sivelestat. The patients were classified as effective (n = 28) if they were weaned from the ventilator within 28 days, or as ineffective groups (n = 25). Patient characteristics were compared between these groups and multivariate logistic regression analysis was used to identify predictive factors. A validation study was then conducted in sivelestat-free patients.
A high red blood cell count and low hydrogen ion concentration were significantly associated with a higher ventilator weaning rate in patients receiving sivelestat. The validation study revealed that the hydrogen ion concentration value also significantly associated with ventilator weaning in patients who did not receive sivelestat.
Although hydrogen ion concentration was inversely associated with the ventilator weaning rate, it did not predict sivelestat efficacy. This study indicated that acute lung injury patients with a high red blood cell count would derive the most benefit from sivelestat administration.
Acute lung injury (ALI) is a complex disorder caused by inflammation in response to conditions such as pneumonia and sepsis. ALI is characterized by a neutrophilic inflammatory response, associated with increased pulmonary vascular permeability . Neutrophil elastase (NE) is one of the proteases released from the neutrophils that accumulate in the lung . It degrades lung connective tissues and enhances lung vasopermeability, resulting in ALI. Furthermore, NE increases the production of neutrophil migration factor and is recognized as an important driver of systemic inflammatory response syndrome (SIRS) .
Sivelestat is a selective NE inhibitor, which binds directly to NE and inactivates it by a reversible acylation-deacylation mechanism [4–6]. In addition, it relaxes vascular smooth muscle . Sivelestat was approved in Japan as a therapeutic drug for ALI associated with SIRS, but is also used in other situations. For example, perioperative administration of sivelestat for esophagectomy improves postoperative respiratory function and shortens the duration of hospitalization and of mechanical ventilation [8–12]. Moreover, sivelestat is administered for pediatric cardiopulmonary bypass surgery because it attenuates the perioperative inflammatory response . Sivelestat also shortens the duration of mechanical ventilation, intensive care unit stay, and hospitalization due to severe respiratory failure after thoracic aortic surgery .
In a post-marketing clinical trial (phase IV) conducted in Japan , the adjusted mean number of ventilator-free days (VFD) was significantly higher in the sivelestat group than in the control group (P = 0.0022). However, the Sivelestat Trial in ALI Patients Requiring Mechanical Ventilation (STRIVE) study  did not identify a significant increase in VFDs in the sivelestat group, as compared with the control group, and the final analysis revealed no effect of sivelestat on VFD (day 1–28). Furthermore, the 180-day all-cause mortality was higher in the sivelestat group than in the control group (P = 0.006). This resulted in the discontinuation of this clinical trial and sivelestat thus failed to receive approval in other countries, such as the USA.
These trials [4, 15] found that the efficacy of sivelestat was inconsistent and it would therefore be beneficial to identify the factors determining the differential effects of sivelestat in patients who respond to treatment, versus the non-responders. The purpose of this case-control study was to identify factors predicting the therapeutic effects of sivelestat.
The case-control study was conducted in compliance with the Strengthening the Reporting of Observational Studies in Epidemiology statement and the Declaration of Helsinki. The protocol (H024-003) was approved by the institutional review board at Kan-etsu hospital (Saitama, Japan). Fifty-three patients on mechanical ventilation, who were administered sivelestat in the hospital from April 2006 to March 2012, were enrolled in this study.
The patients were divided into two groups, according to whether they were categorized as effective or ineffective. Patients in the effective group were weaned from the ventilator within 28 days. VFDs (the primary endpoint of the phase IV study in Japan ) and all-cause mortality (the primary endpoint of the STRIVE study ) were both assessed within 28 days in these studies; we therefore used a 28-day monitoring period in the present study.
Data from the day before sivelestat administration were used for this analysis. If these were unavailable, we used the data from two days before sivelestat administration or from the day of sivelestat administration. Vital signs and SpO2 were not included in the analysis because they were affected by concomitant drugs or ventilation. We initially compared the effective and ineffection group data. We subsequently identified predictive factors using the multivariate analysis described below.
The fators identified using the approach described above may predict the patient response to sivelestat or may represent independent prognostic indicators. To investigate this, we conducted a validation study in the absence of sivelestat. Patients who were using a medical ventilator but were not administered sivelestat were enrolled in Kan-etsu hospital from January 2013 to December 2014. We excluded perioperative patients and those who had been hospitalized for < 24 h from this study.
Patients were divided into two groups, depending on whether they were weaned from the ventilator within 28 days (the weaning group) or not (the no weaning group).
These groups were compared using the approach described in Study design.
We used statistical analyses to investigate which factors predicted the therapeutic effect of sivelestat. We performed an F-test to determine whether each factor exhibited a homoscedastic distribution. A t-test was used in the initial screening of the effective and ineffective groups if the distribution showed homoscedasticity; if not, Welch’s t-test was used. The numbers of male patients, sepsis, and DIC in the two groups were analyzed using the Chi-square test. We then performed multivariate logistic regression analysis (stepwise: likelihood ratio) using SPSS® (SPSS Inc., Chicago, USA) to identify factors that showed a significant association with a high mechanical ventilation weaning rate. We employed the stepwise method because the method is suitable to control confounding factors in multivariate logistic regression analysis.
Profiles of the patients included in the case-control study
Effective group (n = 28)
Ineffective group (n = 25)
67.7 ± 14.5
77.0 ± 8.4
21 (75.0 %)
20 (80.0 %)
8 (28.6 %)
13 (52.0 %)
9 (32.1 %)
11 (44.0 %)
46.8 ± 38.9
29.3 ± 26.4
67.3 ± 61.9
75.1 ± 119.1
569 ± 222
670 ± 744
306 ± 160
500 ± 829
68.9 ± 80.2
40.2 ± 34.6
31.9 ± 20.8
37.3 ± 21.6
2.0 ± 2.7
2.1 ± 2.6
376.1 ± 84.9
327.2 ± 72.1
11,121 ± 7299
13,441 ± 8549
88.4 ± 9.3
85.9 ± 10.3
18.8 ± 9.8
16.0 ± 9.8
3.1 ± 2.0
2.4 ± 0.6
19.6 ± 11.2
15.5 ± 9.4
3.639 ± 0.667
4.422 ± 0.936
93.2 ± 48.1
61.4 ± 24.7
36.6 ± 9.3
47.7 ± 17.5
0.216 ± 0.049
0.209 ± 0.046
Logistic regression analysis
95 % CI
Age and PCO2, which correlated with [H+] and/or PO2, were dropped from the process. Three factors (RBC, [H+], and PO2) were therefore identified as candidates for the prediction of the therapeutic effect of sivelestat.
Profiles of the patients included in the validation study
Weaning ventilator group (n = 56)
Non weaning ventilator group (n = 49)
77.5 ± 14.0
79.1 ± 9.8
29 (51.8 %)
35 (71.4 %)
385.6 ± 72.9
361.7 ± 91.2
4.661 ± 1.534
6.158 ± 3.418
Although the efficacy and safety of Sivelestat in the Japanese patients was demonstrated in the phase III double-blind study and the postparket study, the difference in the 28-day ventilator-weaning rate was only 13 % between the sivelestat and control group in the postparket study and the negative results was reported in the STRIVE study [4, 15, 16]. The reason why the efficacy was small or negative would be the presence of the responder and non-responder. Thus, we attempted to identify factors predicting the therapeutic effects of sivelestat. This case-control study is the first trial to find predictors of the therapeutic effect of sivelestat in patients with ALI associated with SIRS.
We initially evaluated the differences between the effective (ventilator weaning) and ineffective groups of patients who were administered with sivelestat. This logistic regression analysis revealed that three factors, [H+], RBC, and PO2, were significantly associated with the mechanical ventilation weaning rate of these patients.
Formula 1 allows calculation of the probability of sivelestat effectiveness in a patient using the values of these predictive factors. The normal reference values for [H+], RBC, and PO2 are 3.548 × 10−8 (corresponding to a pH of 7.45), 450 (× 104/μL), and 100, respectively. Substitution of these reference values into formula 1 produces a probability of 94 %. If one of these factors ([H+], RBC, or PO2) changed to 5.853 × 10−8 (pH = 7.23), 221, or 8.3, respectively, the probability was reduced to 50 %.
This indicated that PO2 was unlikely to modulate the patient response to sivelestat significantly, because a PO2 value of 8.3 is not realistic in the clinical situation. On the other hand, [H+] and RBC may have greater effect on sivelestat response because a [H+] value of 5.853 × 10−8 (pH = 7.23), or a RBC value of 221 are often observed in hospitalized patients.
Respiratory failure induces severe acidosis, where pulmonary CO2 elimination decreases (respiratory acidosis) and/or an oxygen deficit (lactic acidosis) occurs. Our findings suggested that as respiratory function declined, sivelestat became less effective. Red blood cells transport oxygen within the body and a reduced RBC therefore indicates oxygen deficiency, which necessitates a longer ventilation period.
Although we found two candidate predictive factors in the first study, it was possible that these predicted ventilator weaning, regardless of sivelestat administration. Thus, we conducted a validation study of [H+] and RBC values in patients who did not receive sivelestat.
The mean [H+] value was significantly higher in the no weaning group, as compared with the weaning group, indicating that this parameter predicted ventilator weaning, even in the absence of sivelestat. On the other hand, RBC showed little effect on the weaning rate of these patients, indicating that only RBC predicted the therapeutic effect of sivelestat.
Patients who received dialysis therapy were expected to have variable RBC values. Then, we count number of dialyzing patients in the case-control study. The numbers of dialyzing patients were 8 in the effective group and 6 in the ineffective group. The ratio of the dialyzing patients was not significantly different between the groups (chi-square test, p = 0.706).
Because a few patients were administered sivelestat in Kan-etsu hospital, the patient numbers of effective and ineffective group were 28 and 25, respectively. Such small sample size is limitation of this study. The study of large sample size is needed.
Evaluated [H+], RBC and PO2 levels prior to sivelestat administration predicted that it would produce less therapeutic benefit. The RBC represented a particularly valuable predictor of this therapeutic effect. ALI patients with high RBC levels may be the best candidates for sivelestat administration.
ALI, acute lung injury; NE, neutrophil elastase; SIRS, systemic inflammatory response syndrome; STRIVE, Sivelestat Trial in ALI Patients Requiring Mechanical Ventilation; VFD, ventilator-free days
TO collected the data, performed the statistical analysis, and drafted the manuscript. NY conceived of the study and participated in its design and coordination. KM participated in the design of study and completed the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991;177:814–20.View ArticlePubMedGoogle Scholar
- Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002;451:1–10.View ArticlePubMedGoogle Scholar
- Kodama T, Yukioka H, Kato T, Kato N, Hato F, Kitagawa S. Neutrophil elastase as a predictive factor for development of acute lung injury. Intern Med. 2007;46:699–704.View ArticlePubMedGoogle Scholar
- Aikawa N, Ishizaka A, Hirasawa H, Shimazaki S, Yamamoto Y, Sugimoto H, et al. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulm Pharmacol Ther. 2011;24:549–54.View ArticlePubMedGoogle Scholar
- Nakayama Y, Odagaki Y, Fujita S, Matsuka S, Hamanaka N, Nakai H, et al. Clarification of mechanism of human sputum elastase inhibition by a new inhibitor, ONO-5046, using electrospray ionization mass spectrometry. Bioorg Med Chem Lett. 2002;12:2349–53.View ArticlePubMedGoogle Scholar
- Feng L, Zhu W, Huang C, Li Y. Direct interaction of ONO-5046 with human neutrophil elastase through 1H NMR and molecular docking. Int J Biol Macromol. 2012;51:196–200.View ArticlePubMedGoogle Scholar
- Amemori H, Maeda Y, Torikai A, Nakashima M. Sivelestat relaxes vascular smooth muscle contraction in human gastric arteries. J Physiol Biochem. 2011;67:589–93.View ArticlePubMedGoogle Scholar
- Nagai Y, Watanabe M, Baba Y, Iwatsuki M, Hirashima K, Karashima R, et al. Preventive effect of sivelestat on postoperative respiratory dusorders after thoracic esophagectomy. Surg Today. 2013;43:361–6.View ArticlePubMedGoogle Scholar
- Nishijima J, Matsuda M, Ando S, Hirasawa M, Suzuki T, Makuuchi H. The effects of the early administration of sivelestat sodium, a selective neutrophil elastase inhibitor, on the postoperative course after radical surgery for esophageal cancer. Surg Today. 2012;42:659–65.View ArticleGoogle Scholar
- Mimatsu K, Oida T, Kawasaki A, Kano H, Kuboi Y, Amano S. Influence of neutrophil elastase inhibitor on the postoperative couse in patients with esophageal cancer after transthoracic esophagectomy. Hepatogastroenterology. 2011;58:1583–7.View ArticlePubMedGoogle Scholar
- Yamaguchi K, Sugasawa Y, Takeuchi K, Kugimiya T, Kumakura S, Iwanuma Y, et al. Effects of sivelestat on bronchial inflammatory responses after esophagectomy. Int J Mol Med. 2011;28:187–92.PubMedGoogle Scholar
- Makino H, Kunisaki C, Kosaka T, Akiyama H, Morita S, Endo I. Perioperative use of a neutrophil elastase inhibitor in video-assisted thoracoscopic oesophagectomy for cancer. Br J Surg. 2011;98:975–82.View ArticlePubMedGoogle Scholar
- Inoue N, Oka N, Kitamura T, Tomoyasu T, Miyaji K. Neutrophil elastase inhibitor sivelestat attenuates perioperative inflamattory response in pediatric heart surgery with cardiopulmonary bypass. Int Heart J. 2013;54:149–53.View ArticlePubMedGoogle Scholar
- Morimoto K, Nishimura K, Miyasaka S, Maeta H, Taniguchi I. The effect of sivelestat sodium hydrate on severe respiratory failure after thoracic aortic surgery with deep hypothermia. Ann Thorac Cardiovasc Surg. 2011;17:369–75.View ArticlePubMedGoogle Scholar
- Zeiher BG, Artigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT, Bernard G, STRIVE Study Group. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695–702.View ArticlePubMedGoogle Scholar
- Tamakuma S, Ogawa M, Aikawa N, Kubota T, Hirasawa H, Ishizaka A, Taenaka N, Hamada C, Matsuoka S, Abiru T. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther. 2004;17:271–9.View ArticlePubMedGoogle Scholar